Vertex Pharmaceuticals acquires Catalyst Biosciences' complement portfolio for $60 million

VERTEX PHARMACEUTICALS INC / MA

Vertex acquired Catalyst's complement portfolio and related IP, including CB 2782-PEG, for $60 million cash.
The transaction closed on May 19, 2022, and was disclosed in an 8-K filed May 23, 2022.
Vertex will record the $60 million purchase price in GAAP and non-GAAP operating expenses in Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.